FY2026 Earnings Forecast for VIR Issued By Leerink Partnrs

Vir Biotechnology, Inc. (NASDAQ:VIR) – Leerink Partnrs reduced their FY2026 earnings per share (EPS) estimates for Vir Biotechnology in a research note issued on Wednesday, November 20th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will post earnings of ($4.05) per share for the year, down from their prior estimate of ($3.55). The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.86) per share. Leerink Partnrs also issued estimates for Vir Biotechnology’s FY2027 earnings at ($2.80) EPS.

A number of other analysts have also recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $110.00 price target on shares of Vir Biotechnology in a research note on Wednesday. Needham & Company LLC reissued a “buy” rating and set a $19.00 target price on shares of Vir Biotechnology in a research report on Wednesday. Finally, Barclays lowered their price target on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $36.40.

Vir Biotechnology Trading Up 2.4 %

Vir Biotechnology stock opened at $7.12 on Friday. The company has a fifty day simple moving average of $7.91 and a 200-day simple moving average of $8.87. The stock has a market cap of $980.57 million, a P/E ratio of -1.82 and a beta of 0.46. Vir Biotechnology has a 12-month low of $6.56 and a 12-month high of $13.09.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The firm had revenue of $2.38 million for the quarter, compared to analyst estimates of $5.54 million. During the same quarter last year, the firm earned ($1.22) EPS. The company’s revenue was down 9.8% on a year-over-year basis.

Institutional Investors Weigh In On Vir Biotechnology

Several large investors have recently modified their holdings of the stock. Louisiana State Employees Retirement System raised its holdings in Vir Biotechnology by 2.8% during the second quarter. Louisiana State Employees Retirement System now owns 43,800 shares of the company’s stock worth $390,000 after purchasing an additional 1,200 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of Vir Biotechnology by 8.4% during the 1st quarter. ProShare Advisors LLC now owns 26,392 shares of the company’s stock worth $267,000 after buying an additional 2,035 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Vir Biotechnology by 143.5% in the 3rd quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after buying an additional 2,351 shares during the period. Public Sector Pension Investment Board boosted its stake in shares of Vir Biotechnology by 1.4% in the third quarter. Public Sector Pension Investment Board now owns 194,208 shares of the company’s stock valued at $1,455,000 after buying an additional 2,600 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Vir Biotechnology by 15.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,647 shares of the company’s stock worth $219,000 after acquiring an additional 3,215 shares during the period. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Insider Buying and Selling

In other Vir Biotechnology news, Director Janet Napolitano sold 12,190 shares of Vir Biotechnology stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $7.80, for a total value of $95,082.00. Following the transaction, the director now directly owns 11,616 shares in the company, valued at approximately $90,604.80. This trade represents a 51.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 15,940 shares of company stock worth $127,410 in the last 90 days. Company insiders own 15.60% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).